Current pharmacological interventions for AD encompass cholinesterase inhibitors such as donepezil and rivastigmine, which mitigate cholinergic deficits, and NMDA (N-methyl-D-aspartate) receptor antagonists such as memantine, which modulate excitotoxic glutamatergic signaling. The gene discussed is BCHE; the disease is Alzheimer disease.